ML | pharmaphorum

R&D

As the drug development landscape becomes more complex, pharmaceutical and biotech companies understand their business strategies have to evolve.

News

Astellas takes an option on a cancer immunotherapy developed by Audax for up to $1.34bn, with Gilead and Teva also adding to their pipelines.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

ML